Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 16/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | FPR3 | P25089 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798834 | 1.00 | ADRB2 (0.57) | ADRB2ADRB1ADRB3CYP2D6KDM4E | |
| SCHEMBL668538 | 1.00 | ADRB2 (0.57) | ADRB2ADRB1ADRB3CYP2D6KDM4E | |
| SCHEMBL185382 | 0.84 | ADRB2 (0.69) | ADRB2ADRB1ADRB3CYP2D6KDM4E | |
| SCHEMBL30510394 | 0.84 | ADRB2 (0.69) | ADRB2ADRB1ADRB3CYP2D6KDM4E | |
| SCHEMBL28335500 | 0.84 | ADRB2 (0.69) | ADRB2ADRB1ADRB3CYP2D6KDM4E | |
| SCHEMBL185383 | 0.84 | ADRB2 (0.69) | ADRB2ADRB1ADRB3CYP2D6KDM4E | |
| SCHEMBL11189856 | 0.84 | ADRB2 (0.66) | ADRB2ADRB1ADRB3CYP2D6KDM4E | |
| SCHEMBL185697 | 0.84 | ADRB2 (0.58) | ADRB2ADRB1ADRB3CYP2D6KDM4E | |
| SCHEMBL9938462 | 0.84 | ADRB2 (0.58) | ADRB2ADRB1ADRB3CYP2D6KDM4E | |
| SCHEMBL20162374 | 0.83 | ADRB2 (0.57) | ADRB2ADRB1ADRB3CYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242177-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2012-08-14 | — | — | US | claimed |
| US-20120101075-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor | LABORATORIOS ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | US | claimed |
| EP-1885684-B9 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-04-25 | — | — | EP | claimed |
| EP-1885684-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2011-07-13 | — | — | EP | claimed |
| EP-2263998-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor | Almirall S.A. (ES) | 2010-12-22 | — | — | EP | claimed |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3436446-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3925607-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-2079731-A1 | NOVEL SUBSTITUTED PIPERIDYL-PROPANE-THIOLS | Boehringer Ingelheim International GmbH (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| EP-1953163-A1 | Pteridinone derivatives as PI3-kinases inhibitors | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008049875-A1 | NOVEL SUBSTITUTED PIPERIDYL-PROPANE-THIOLS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008049874-A1 | PIPERIDYL-PROPANE-THIOL CCR3 MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-02 | — | — | WO | disclosed |
| EP-1885684-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006122788-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | ADRB2 522/4885ADRB1 308/4885ADRB3 421/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ADRB2 522/4885ADRB1 308/4885ADRB3 421/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ADRB2 522/4885ADRB1 308/4885ADRB3 421/4885 |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885ADRB3 4/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | ADRB2 522/4885ADRB1 308/4885ADRB3 421/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | ADRB2 1836/4885ADRB1 1307/4885ADRB3 1299/4885 |
| US-20120101075-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.